About
About Samjin Pharmaceuticals Co., Ltd
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Visit company website
5 years, 5 months ago
Samjin Pharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.
From a valuation standpoint, the stock is 84.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Samjin Pharmaceuticals Co., Ltd's total revenue rose by 0.4% to $59B since the same quarter in the previous year.
Its net income has increased by 149.6% to $6B since the same quarter in the previous year.
Finally, its free cash flow fell by 227.8% to $-13B since the same quarter in the previous year.
Based on the above factors, Samjin Pharmaceuticals Co., Ltd gets an overall score of 4/5.